Akeso Inc - ESG Rating & Company Profile powered by AI
The analysis of Akeso Inc was assembled by All Street Sevva using leading Cognitive Robots. The assessment of Akeso Inc uses data from across the internet and also from available documents by Akeso Inc. The Disclosure score covers 17 United Nations SDGs including: 'No Poverty', 'Responsible Production & Consumption' and 'Life on Land'.
Akeso Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.5; made up of an environmental score of 0.0, social score of 3.4 and governance score of 4.0.
2.5
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1481 | Tissue Regenix Group PLC | 2.6 | Medium |
| 1481 | Twist Bioscience Corp | 2.6 | Medium |
| 1499 | Akeso Inc | 2.5 | Medium |
| 1499 | Allergan plc | 2.5 | Medium |
| 1499 | Joinn Laboratories China Co Ltd | 2.5 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Akeso Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Akeso Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Akeso Inc report the average age of the workforce?
Sign up for free to unlockDoes Akeso Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Akeso Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Akeso Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Akeso Inc offer flexible work?
Sign up for free to unlockDoes Akeso Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Akeso Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Akeso Inc conduct supply chain audits?
Sign up for free to unlockDoes Akeso Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Akeso Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Akeso Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Akeso Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Akeso Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Akeso Inc disclose water use targets?
Sign up for free to unlockDoes Akeso Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Akeso Inc have a product recall in the last two years?
Sign up for free to unlockDoes Akeso Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Akeso Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Akeso Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Akeso Inc disclose parental leave metrics?
Sign up for free to unlockDoes Akeso Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Akeso Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Akeso Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Akeso Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Akeso Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Akeso Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Akeso Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Akeso Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Akeso Inc disclose its waste policy?
Sign up for free to unlockDoes Akeso Inc report according to TCFD requirements?
Sign up for free to unlockDoes Akeso Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Akeso Inc disclose energy use targets?
Sign up for free to unlockDoes Akeso Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Akeso Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Akeso Inc
These potential risks are based on the size, segment and geographies of the company.
Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) adenocarcinoma, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), clear cell renal cell carcinoma, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat solid and gynecological tumors, NSCLC, SCLC, and triple-negative breast cancer (TNBC). It is also developing AK105, a PD-1 monoclonal antibody to treat NSCLC, NPC, classic Hodgkin's lymphoma (R/R cHL), HCC, head and neck cancer, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, TNBC, HNSCC, R/R cHL, NPC, NSCLC, and solid tumors/lymphoma; AK119, a CD73 monoclonal antibody for treating solid tumors; and AK109, a VEGFR-2 monoclonal antibody to treat solid tumors and gastric cancer. In addition, the company develops AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis and asthma, and eosinophilic esophagitis; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia. Further, its preclinical product includes AK127, a TIGIT monoclonal antibody to treat solid tumors; and AK115, a NGF monoclonal antibody. The company has collaboration agreements with Pfizer Pharmaceuticals, AstraZeneca Pharmaceuticals, and MD Anderson Medical Institute. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.